TABLE III.

Patient and Disease Characteristics at Bleeding in Association with Mortality

Variable	Dead	Median (range)	N	No. dead (%)	P
Age (years), bleed	Y	60 (21–80)			0.005
	N	48 (14–78)
Wbc, bleed	Y	3.25 (0–185.6)			0.30
	N	1.55 (0.1–116.4)
ANC, bleed	Y	0.65 (0–27.73)			0.98
	N	1.03 (0–27.7)
Hgb, bleed	Y	8.9 (4.5–14.6)			0.27
	N	9.4 (4.5–14.7)
Plt, bleed	Y	21 (0–318)			0.55
	N	16 (1–208)
Blast% bleed	Y	2 (0–99)			0.02
	N	0 (0–94)
PTT, bleed	Y	29.6 (16.8–66.2)			0.22
	N	28.9 (21.9–38.8)
INR, bleed	Y	1.48 (0.36–12.3)			0.01
	N	1.27 (0.95–3.23)
Fibrinogen, bleed	Y	494 (6–768)			0.15
	N	628 (190–897)
Days from DX to bleed	Y	208 (4–1923)			0.11
	N	106 (0–1099)
Creat, bleed	Y	0.9 (0.3–3.8)			0.09
	N	0.75 (0.4–1.7)
Bili, bleed	Y	0.8 (0.1–18.2)			0.21
	N	0.6 (0.1–23.3)
Albumin, bleed	Y	3 (1.4–4.9)			0.003
	N	3.6 (2–4.4)
LDH, bleed	Y	968 (101–36082)			0.005
	N	524 (49–5294)
Sex
Female			60	44 (73)	0.52
Male			58	46 (79)
Bleed onset
Ind CR			18	6 (33)	< 0.001
No RX			3	2 (67)
On ind			39	30 (77)
Relapsed/multirx			58	52 (90)
Leukemia subtype
ALL			19	12 (63)	0.19
AML			71	55 (78)
CML			15	14 (93)
MDS			13	9 (69)
Prior malignancy,
Yes			26	22 (85)	0.31
No			92	68 (74)
Rx, prior malignancy
Chemo+X			9	7 (78)	0.48
Chemo only			7	7 (100)
X-ray only			3	3 (100)
No rx (inc. no prior malignancy)			99	73 (74)
Bleeding site
ED			2	2 (100)	0.53
IP			67	52 (78)
SD			34	26 (77)
SAH			12	7 (58)
Two			3	3 (100)
Surgery Intervention
No			106	79 (75)	0.29
Yes			12	11 (92)